AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25552609 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 3 days/week
Number of subjects: 45
Study 25552609 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 45
Study 22191456 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Choices motivational interviewing intervention
Number of subjects: 143
Study 22191456 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 20144858 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term humidification therapy
Number of subjects: 108
Study 20144858 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study 18564957 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly applied mud pack treatment (heated mud, up to 43 degrees C, applied directly for 30 minutes, 15 applications)
Number of subjects: 60
Study 18564957 — intervention group
Group type: COMPARATOR
Intervention: Nylon-covered mud pack treatment (same treatment as study group but with nylon cover)
Number of subjects: 60
Study 15904531 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking for transport
Number of subjects: 7247
Study 15904531 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking for exercise
Number of subjects: 7247
Study 12884156 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 21
Study 12884156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9884381 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (10 micromol/L)
Number of subjects: 10
Study 9884381 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinterol (10 micromol/L)
Number of subjects: 10
Study 9884381 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (10 micromol/L)
Number of subjects: 10
Study 9116480 — intervention group
Group type: EXPERIMENTAL
Intervention: Function‐Oriented Guidance (FOG)
Number of subjects: 0
Study 9116480 — intervention group
Group type: COMPARATOR
Intervention: Function Training (FT)
Number of subjects: 0
Study 1884968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10000 adrenalin injection
Number of subjects: 83
Study 1884968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10000 adrenalin +1% aethoxysclerol injection
Number of subjects: 83
Study 1884968 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe
Number of subjects: 83
Study 6804110 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 21
Study 29761722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue: Take Control (FTC)
Number of subjects: 74
Study 29761722 — intervention group
Group type: COMPARATOR
Intervention: MS: Take Control (MSTC)
Number of subjects: 74
Study 28653767 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood condition
Number of subjects: 270
Study 28653767 — intervention group
Group type: COMPARATOR
Intervention: Negative mood condition
Number of subjects: 270
Study 27430294 — intervention group
Group type: EXPERIMENTAL
Intervention: ESA decision aid
Number of subjects: 0
Study 27430294 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 23932092 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐NBI after C‐WLI
Number of subjects: 353
Study 23932092 — intervention group
Group type: COMPARATOR
Intervention: M‐NBI
Number of subjects: 353
Study 23932092 — intervention group
Group type: COMPARATOR
Intervention: C‐WLI
Number of subjects: 353
Study 22253296 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg/d of elemental calcium carbonate plus 400 IU/d of vitamin D(3)
Number of subjects: 330
Study 22253296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 20598973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of autologous bone marrow mononucleated cells (BM‐MNCs) at 5 to 7 days after AMI
Number of subjects: 192
Study 20598973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of autologous bone marrow mononucleated cells (BM‐MNCs) at 3 to 4 weeks after AMI
Number of subjects: 192
Study 20598973 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art medical management (Control)
Number of subjects: 192
Study 17683456 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory white noise during cognitive tasks (self‐performed mini tasks and verbal tasks)
Number of subjects: 0
Study 17683456 — intervention group
Group type: COMPARATOR
Intervention: No auditory white noise during cognitive tasks
Number of subjects: 0
Study 15613506 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (3 mg/kg/day) in the iron supplemented (IS) group; n = 37
Number of subjects: 73
Study 15613506 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops in the placebo (P) group; n = 36
Number of subjects: 73
Study 12757987 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 45
Study 12757987 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 45
Study 10536353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyto-Tek MonoPrep (MP) system
Number of subjects: 44
Study 10536353 — intervention group
Group type: COMPARATOR
Intervention: Conventional smear (CS) preparation
Number of subjects: 44
Study 8660148 — intervention group
Group type: EXPERIMENTAL
Intervention: Presymptomatic gene carriers (GCs)
Number of subjects: 383
Study 8660148 — intervention group
Group type: COMPARATOR
Intervention: Non-gene carriers (non-GCs)
Number of subjects: 383
Study 8660148 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene carriers (GCs)
Number of subjects: 383
Study 2008130 — intervention group
Group type: EXPERIMENTAL
Intervention: Terodiline (25 mg daily)
Number of subjects: 42
Study 2008130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7140008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake
Number of subjects: 182
Study 30482255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sahaj Samadhi meditation (SSM)
Number of subjects: 83
Study 30482255 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 83
Study 26359286 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstably-housed adults living with HIV
Number of subjects: 0
Study 26359286 — intervention group
Group type: COMPARATOR
Intervention: Stably-housed adults living with HIV
Number of subjects: 0
Study 26359286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 25526014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit Minded Tablet (n=15)
Number of subjects: 30
Study 25526014 — intervention group
Group type: COMPARATOR
Intervention: Standard Fit Minded (n=15)
Number of subjects: 30
Study 24030535 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyaluronic acid (HA) and tamarind seed polysaccharide (TS‐polysaccharide)
Number of subjects: 49
Study 24030535 — intervention group
Group type: COMPARATOR
Intervention: Carmellose sodium
Number of subjects: 49
Study 22939764 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation for 16 weeks
Number of subjects: 41
Study 22939764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 19954391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 64
Study 19954391 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate 0.1% cream
Number of subjects: 64
Study 19954391 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel
Number of subjects: 64
Study 17334090 — intervention group
Group type: EXPERIMENTAL
Intervention: Kakisu (persimmon vinegar) for 56 days (Group A)
Number of subjects: 81
Study 17334090 — intervention group
Group type: EXPERIMENTAL
Intervention: Kakisu (persimmon vinegar) for 54 days (Group B)
Number of subjects: 81
Study 17334090 — intervention group
Group type: EXPERIMENTAL
Intervention: Kakisu (persimmon vinegar)
Number of subjects: 81
Study 10773104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy (400 mg/day for 14 days every 3 months) followed by 500 mg/day of elemental calcium for 1 year
Number of subjects: 121
Study 10773104 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by 500 mg/day of elemental calcium for 1 year
Number of subjects: 121
Study 8643695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 0.10 mg/kg per day for 7 days as four monthly courses (total 2.8 mg/kg)
Number of subjects: 0
Study 8643695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine i.v. infusions of 0.10 mg, 0.05 mg, and 0.05 mg per kg of body weight per day for 7 consecutive days in three successive monthly courses (total 1.4 mg/kg)
Number of subjects: 0
Study 8643695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1282619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg twice daily)
Number of subjects: 17
Study 1282619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2870001 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral acidification (pH allowed to decrease)
Number of subjects: 19
Study 2870001 — intervention group
Group type: COMPARATOR
Intervention: pH maintained at 4.5
Number of subjects: 19
Study 30898234 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAC Gold
Number of subjects: 70
Study 30898234 — intervention group
Group type: COMPARATOR
Intervention: Thermocool
Number of subjects: 70
Study 30898234 — intervention group
Group type: EXPERIMENTAL
Intervention: Both catheters
Number of subjects: 70
Study 30183437 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute voice rest
Number of subjects: 20
Study 30183437 — intervention group
Group type: COMPARATOR
Intervention: Relative voice rest
Number of subjects: 20
Study 26087884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (cycling for at least 15 minutes daily for 15 months)
Number of subjects: 114
Study 26087884 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary recreational activities)
Number of subjects: 114
Study 24372367 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention in addition to standard care
Number of subjects: 0
Study 24372367 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 22883401 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (White Ball exercises)
Number of subjects: 16
Study 22883401 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list with no qigong instruction)
Number of subjects: 16
Study 20739450 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond skin phenolic extract (884 mg of total polyphenols/dose)
Number of subjects: 16
Study 20739450 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 16
Study 18076261 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated bout (RB) condition
Number of subjects: 31
Study 18076261 — intervention group
Group type: COMPARATOR
Intervention: Single bout (CON) condition
Number of subjects: 31
Study 16463656 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (12 g/L in ST. Thomas cardioplegia)
Number of subjects: 23
Study 11996470 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A (carboplatin AUC 4 with topotecan 0.5 or 0.75 mg/m2)
Number of subjects: 21
Study 11996470 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B (carboplatin AUC 4 with topotecan 0.5 or 0.75 mg/m2)
Number of subjects: 21
Study 10520026 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission
Number of subjects: 1711
Study 10520026 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial remission
Number of subjects: 1711
Study 10520026 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant disease
Number of subjects: 1711
Study 10520026 — intervention group
Group type: EXPERIMENTAL
Intervention: Favourable karyotype
Number of subjects: 1711
Study 10520026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate karyotype
Number of subjects: 1711
Study 10520026 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse karyotype
Number of subjects: 1711
Study 10520026 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB type M3 without cytogenetic t(15;17)
Number of subjects: 1711
Study 10520026 — intervention group
Group type: EXPERIMENTAL
Intervention: Good risk group (favourable karyotype or M3)
Number of subjects: 1711
Study 10520026 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard risk group (neither good nor poor)
Number of subjects: 1711
Study 10520026 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor risk group (adverse karyotype or resistant disease)
Number of subjects: 1711
Study 7655177 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density of the neck of femur
Number of subjects: 382
Study 7655177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip axis length
Number of subjects: 382
Study 7655177 — intervention group
Group type: EXPERIMENTAL
Intervention: Singh grade
Number of subjects: 382
Study 7655177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hip axis length and bone mineral density
Number of subjects: 382
Study 7655177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Singh grade, hip axis length, and bone mineral density
Number of subjects: 382
Study 2119677 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam once daily for 8 days (days 5-12)
Number of subjects: 16
Study 2119677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 8 days, days 5-12)
Number of subjects: 16
Study 2119677 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg glibenclamide once daily for 12 days
Number of subjects: 16
Study 2119677 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide plasma concentration-time curve
Number of subjects: 16
Study 2119677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean oral clearance of tenoxicam
Number of subjects: 16
Study 31387385 — intervention group
Group type: EXPERIMENTAL
Intervention: Color range indicator (CRI)‐based glucose meters (OneTouch Verio Flex)
Number of subjects: 0
Study 31387385 — intervention group
Group type: EXPERIMENTAL
Intervention: Color range indicator (CRI)‐based glucose meters (OneTouch Verio)
Number of subjects: 0
Study 31387385 — intervention group
Group type: COMPARATOR
Intervention: Control group (GMs without a CRI)
Number of subjects: 0
Study 28011003 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game playing (VGP)
Number of subjects: 31
Study 28011003 — intervention group
Group type: COMPARATOR
Intervention: Television viewing (TVV)
Number of subjects: 31
Study 28011003 — intervention group
Group type: COMPARATOR
Intervention: Challenging computer task (CT)
Number of subjects: 31
Study 28011003 — intervention group
Group type: COMPARATOR
Intervention: Sitting without screen exposure (control)
Number of subjects: 31
Study 26034367 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sequential therapy (Group B): ilaprazole at 5 mg bid, amoxicillin and clavulanate potassium at 914 mg for the first five days, followed by ilaprazole at 5 mg bid, furazolidone at 100 mg bid, and levofloxacin at 500 mg qid for the next five days.
Number of subjects: 200
Study 26034367 — intervention group
Group type: COMPARATOR
Intervention: Standard quadruple therapy (Group A): ilaprazole + bismuth potassium citrate + amoxicillin and clavulanate potassium + levofloxacin.
Number of subjects: 200
Study 26034367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 200
Study 23868286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐intervention intravascular ultrasound (IVUS)
Number of subjects: 62
Study 21443567 — intervention group
Group type: EXPERIMENTAL
Intervention: ARI+Li/Val
Number of subjects: 337
Study 21443567 — intervention group
Group type: COMPARATOR
Intervention: PLB+Li/Val
Number of subjects: 337
Study 19890021 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant LH
Number of subjects: 3
Study 19890021 — intervention group
Group type: COMPARATOR
Intervention: Wild-type LH
Number of subjects: 3
Study 17420159 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil (two enteric-coated capsules twice per day)
Number of subjects: 57
Study 17420159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 15815889 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient topical treatment with dithranol and narrow band UV‐B 311 nm
Number of subjects: 74
Study 15815889 — intervention group
Group type: COMPARATOR
Intervention: Biologics treatment with efalizumab
Number of subjects: 74
Study 11964576 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume preparation of botulinum toxin-A (60 units)
Number of subjects: 13
Study 11964576 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume preparation of botulinum toxin-A (60 units)
Number of subjects: 13
Study 9654560 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated tears of lateral complete discoid meniscus, lateral incomplete discoid, or lateral semilunar meniscus
Number of subjects: 385
Study 9654560 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated tears of medial semilunar meniscus without obvious trauma
Number of subjects: 385
Study 8749612 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine administered by steady-state, continuous intravenous infusion
Number of subjects: 9
Study 2677915 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative functional treatment
Number of subjects: 44
Study 2677915 — intervention group
Group type: COMPARATOR
Intervention: Operative functional treatment
Number of subjects: 44
Study 421639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryodestruction
Number of subjects: 26
Study 421639 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed operative hemorrhoidectomy
Number of subjects: 26
Study 29699717 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone referral from Primary Health Care to Internal Medicine Consult
Number of subjects: 154
Study 29699717 — intervention group
Group type: COMPARATOR
Intervention: Traditional referral from Primary Health Care to Internal Medicine Consult
Number of subjects: 154
Study 29699717 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practitioners in the intervention group
Number of subjects: 154
Study 29699717 — intervention group
Group type: COMPARATOR
Intervention: General Practitioners in the control group
Number of subjects: 154
Study 29699717 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practitioners in the test group
Number of subjects: 154
Study 28701637 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants (Fuji Triage)
Number of subjects: 35
Study 28701637 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealants (Clinpro)
Number of subjects: 35
Study 28701637 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 25742735 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body resistance exercise (ULB)
Number of subjects: 0
Study 25742735 — intervention group
Group type: COMPARATOR
Intervention: Lower-body resistance exercise (LB)
Number of subjects: 0
Study 23893083 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 152
Study 23893083 — intervention group
Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 152
Study 21537293 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer compression bandaging
Number of subjects: 0
Study 21537293 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial dressings
Number of subjects: 0
Study 19491016 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-NC100692, intravenous injection of 150 micrograms
Number of subjects: 0
Study 19491016 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-NC100692
Number of subjects: 0
Study 16982293 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg intravenously every 8 hours
Number of subjects: 1076
Study 16982293 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg intravenously every 8 hours
Number of subjects: 1076
Study 15579755 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione (100 mg)
Number of subjects: 10
Study 11138835 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal cautery after surgical incision and drainage
Number of subjects: 100
Study 11138835 — intervention group
Group type: COMPARATOR
Intervention: No thermal cautery after surgical incision and drainage
Number of subjects: 100
Study 9296414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 14
Study 9296414 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 14
Study 9296414 — intervention group
Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 14
Study 8361987 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg regular aspirin daily (14 pills)
Number of subjects: 52
Study 8361987 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg regular aspirin daily (14 pills)
Number of subjects: 52
Study 8361987 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg enteric-coated aspirin daily (14 pills)
Number of subjects: 52
Study 8361987 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg regular aspirin every other day (7 pills)
Number of subjects: 52
Study 8361987 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg daily aspirin
Number of subjects: 52
Study 3791663 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg p.o. at 2200 and 2400 h)
Number of subjects: 6
Study 3791663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29388085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular combined with intraosseous injection of PRP (administered twice, 2 weeks apart)
Number of subjects: 86
Study 29388085 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection of PRP (every 14 days)
Number of subjects: 86
Study 29388085 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular HA (five injections every 7 days)
Number of subjects: 86
Study 26928796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 111
Study 26928796 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 111
Study 26928796 — intervention group
Group type: COMPARATOR
Intervention: Control (Intravenous saline infusion)
Number of subjects: 111